SCHEMBL2931976

SCHEMBL2931976

CCOC(=O)c1cc(O)c2ccc(-c3ccc(F)cc3)cc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.49
PTPN11 Q06124 2/20 0.48
SLC6A2 P23975 1/20 0.48
P2RY14 Q15391 1/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
TRPM8 Q7Z2W7 1/20 0.46
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
CASP3 P42574 1/20 0.45
KMT2A Q03164 1/20 0.45
TRPV1 Q8NER1 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
CHRNA7 P36544 1/20 0.44
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30299154 0.89 BCL2L1 (0.53) BCL2L1PTPN11CA12CA1CA2
SCHEMBL2805615 0.89 BCL2L1 (0.53) BCL2L1PTPN11CA12CA1CA2
SCHEMBL2935252 0.86 P2RY14 (0.67) BCL2L1PTPN11SLC6A2P2RY14CA12
SCHEMBL2934955 0.85 BCL2L1 (0.47) BCL2L1PTPN11SLC6A2P2RY14CA12
SCHEMBL30260014 0.81 PTPN11 (0.54) BCL2L1PTPN11CA12CA1CA2
SCHEMBL13057633 0.81 BCL2L1 (0.56) BCL2L1PTPN11CA12CA1CA2
SCHEMBL16479443 0.80 CA12 (0.58) BCL2L1PTPN11SLC6A2P2RY14CA12
SCHEMBL2934388 0.79 ALDH1A1 (0.41) BCL2L1TRPM8MAPTMEN1CASP3
SCHEMBL4395647 0.79 LMNA (0.55) BCL2L1PTPN11CA12CA1CA2
SCHEMBL2932838 0.79 BCL2L1 (0.53) BCL2L1PTPN11CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298347-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY MERCK FROSST CANADA LTD (CA) 2010-11-25 US disclosed
EP-2229373-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY Merck Frosst Canada Ltd. (CA) 2010-09-22 EP disclosed
WO-2009070873-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY MERCK FROSST CANADA LTD. (CA) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298347-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY GPR119, GPR52, GPR35 BCL2L1 2070/4885PTPN11 2850/4885SLC6A2 1169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.